Kalenak 1996.

Methods	Study design: parallel group, randomized controlled trial Number randomized: 25 eyes of 25 participants Exclusions after randomization: none reported Number analyzed: 25 eyes of 25 participants Unit of analysis: participant (one study eye per participant) Handling of missing data: none reported Sample size calculation: not reported
Participants	Country: USA Mean age: not reported Gender: not reported Inclusion criteria: glaucoma with inadequately controlled IOP; at least one previous glaucoma filtering operation Exclusion criteria: neovascular glaucoma Equivalence of baseline characteristics: not reported Diagnoses in participants: non‐neovascular glaucoma
Interventions	MMC group (n = 12): single‐plate Molteno implant with MMC (0.2 mg/mL) No MMC group (n = 13): single‐plate Molteno implant with placebo for 5 minutes
Outcomes	Outcomes (primary and secondary outcomes not differentiated): mean IOP; surgical success, defined as IOP between 6 and 21 mmHg Length of follow‐up: "6 months or more, or to a defined endpoint"
Notes	Study period: not reported Trial registration: not reported Funding and conflicts of interest: not reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Method of sequence generation not reported
Allocation concealment (selection bias)	Unclear risk	Allocation concealment not reported
Masking of participants and personnel (performance bias)	Unclear risk	Masking of participants and personnel not reported
Masking of outcome assessment (detection bias)	Unclear risk	Masking of outcome assessors not reported
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Missing data not reported
Selective reporting (reporting bias)	High risk	No full‐length paper published more than 20 years after presenting the trial at a conference
Other bias	Low risk	None identified